The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
ANI Pharmaceuticals Inc (NASDAQ: ANIP) closed the day trading at $62.30 down -6.03% from the previous closing price of $66.30. In other words, the price has decreased by -$6.03 from its previous closing price. On the day, 0.75 million shares were traded.
Ratios:
For a better understanding of ANIP, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.67 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 20.19. For the most recent quarter (mrq), Quick Ratio is recorded 1.98 and its Current Ratio is at 2.66. In the meantime, Its Debt-to-Equity ratio is 1.55 whereas as Long-Term Debt/Eq ratio is at 1.52.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on March 14, 2025, initiated with a Buy rating and assigned the stock a target price of $80.
On March 12, 2025, JP Morgan started tracking the stock assigning a Overweight rating and target price of $85.
On December 11, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $80.Leerink Partners initiated its Outperform rating on December 11, 2024, with a $80 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 09 ’25 when Shanmugam Muthusamy bought 700 shares for $76.77 per share.
Cook Meredith sold 400 shares of ANIP for $27,584 on Apr 14 ’25. The SR. VP, GENERAL COUNSEL & SEC. now owns 80,145 shares after completing the transaction at $68.96 per share. On Mar 19 ’25, another insider, Davis Krista, who serves as the SVP, CHIEF HR OFFICER of the company, sold 1,866 shares for $65.00 each. As a result, the insider received 121,290 and left with 64,659 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 2.00 while its Price-to-Book (P/B) ratio in mrq is 3.23.
Stock Price History:
Over the past 52 weeks, ANIP has reached a high of $77.00, while it has fallen to a 52-week low of $52.50. The 50-Day Moving Average of the stock is -6.30%, while the 200-Day Moving Average is calculated to be 3.06%.
Shares Statistics:
A total of 21.66M shares are outstanding, with a floating share count of 17.87M. Insiders hold about 17.23% of the company’s shares, while institutions hold 87.80% stake in the company.
Earnings Estimates
The current market rating for ANI Pharmaceuticals Inc (ANIP) reflects the collective analysis of 4.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0.21, with high estimates of $0.43 and low estimates of -$0.06.
Analysts are recommending an EPS of between $2.15 and $1.12 for the fiscal current year, implying an average EPS of $1.54. EPS for the following year is $2.73, with 4.0 analysts recommending between $5.09 and $1.3.
Revenue Estimates
8 analysts predict $188.03M in revenue for the current quarter. It ranges from a high estimate of $192.09M to a low estimate of $181.1M. As of the current estimate, ANI Pharmaceuticals Inc’s year-ago sales were $138.04MFor the next quarter, 8 analysts are estimating revenue of $192.92M. There is a high estimate of $199.01M for the next quarter, whereas the lowest estimate is $189.69M.
A total of 8 analysts have provided revenue estimates for ANIP’s current fiscal year. The highest revenue estimate was $796.55M, while the lowest revenue estimate was $769.7M, resulting in an average revenue estimate of $781.98M. In the same quarter a year ago, actual revenue was $614.38MBased on 8 analysts’ estimates, the company’s revenue will be $840.7M in the next fiscal year. The high estimate is $867.5M and the low estimate is $819.21M.
